Diamyd Medical

Diamyd Medical has developed the diabetes vaccine Diamyd, an antigen-specific immunotherapy based on an exclusively licensed GAD molecule. GABA, together with the diabetes vaccine, constitutes a significant asset for Diamyd Medical, and the company has utilized its GABA licensing technology to develop proprietary GABA drug products.